Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mammary Carcinoma, Human”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT05709158
What this trial is testing

Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

Who this might be right for
Breast Cancer
Pfizer 4,184
Not applicableEnded earlyNCT00904514
What this trial is testing

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 241
Testing effectiveness (Phase 2)Looking for participantsNCT05150691
What this trial is testing

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumor
DualityBio Inc. 796
Early research (Phase 1)Ended earlyNCT03284723
What this trial is testing

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

Who this might be right for
Breast Neoplasms
Pfizer 95
Testing effectiveness (Phase 2)Study completedNCT03251768
What this trial is testing

Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients

Who this might be right for
Chemotherapy-induced Neutropenia
Tianjin SinoBiotech Ltd. 80
Testing effectiveness (Phase 2)Study completedNCT02970682
What this trial is testing

SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer

Who this might be right for
Breast Neoplasm
Evgen Pharma 60
Testing effectiveness (Phase 2)Ended earlyNCT01918306
What this trial is testing

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor Negative Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastTriple Negative Breast Cancer+3 more
Vanderbilt-Ingram Cancer Center 11
Early research (Phase 1)Looking for participantsNCT07046923
What this trial is testing

LY4175408 in Participants With Advanced Cancer

Who this might be right for
Carcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaEndometrial Neoplasms+2 more
Eli Lilly and Company 240
Testing effectiveness (Phase 2)Looking for participantsNCT04787042
What this trial is testing

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Who this might be right for
CancerSolid TumorMelanoma+6 more
Simcha IL-18, Inc. 316
Testing effectiveness (Phase 2)Study completedNCT00875979
What this trial is testing

Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 67
Large-scale testing (Phase 3)Study completedNCT05375461
What this trial is testing

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

Who this might be right for
HR-positive,HER2-negative in Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 293
Early research (Phase 1)Ended earlyNCT02824575
What this trial is testing

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

Who this might be right for
Breast CancerBreast AdenocarcinomaHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast+2 more
Montefiore Medical Center 28
Early research (Phase 1)Study completedNCT04504669
What this trial is testing

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Who this might be right for
Clear Cell Renal Cell CancerNon-Small-Cell Lung CancerTriple Negative Breast Neoplasms+6 more
AstraZeneca 60
Early research (Phase 1)Study completedNCT04054986
What this trial is testing

Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 6
Not applicableEnded earlyNCT03407040
What this trial is testing

Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy

Who this might be right for
Gastrointestinal CancersBreast CancerPancreatic Cancer+2 more
National Cancer Institute (NCI) 98
Not applicableStudy completedNCT07498413
What this trial is testing

Epidemiology and Treatment of HR+/HER2- Breast Cancer in England

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 218,677
Testing effectiveness (Phase 2)Active Not RecruitingNCT02734290
What this trial is testing

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Providence Health & Services 29
Large-scale testing (Phase 3)Active Not RecruitingNCT04639986
What this trial is testing

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Who this might be right for
Metastatic Breast Cancer
Gilead Sciences 331
Large-scale testing (Phase 3)Ended earlyNCT04740918
What this trial is testing

Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 96
Early research (Phase 1)Ended earlyNCT04060342
What this trial is testing

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic AdenocarcinomaEsophageal AdenocarcinomaEsophageal Squamous Cell Carcinoma+11 more
GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. 61
Next Page